fluorouracil has been researched along with Cachexia in 24 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nedaplatin (NDP)/5-fluorouracil (5-FU) combination therapy frequently causes severe neutropenia and febrile neutropenia (FN)." | 8.31 | Poor Renal Function and a High Modified Glasgow Prognostic Score Are Predictive Factors for Nedaplatin/5-Fluorouracil Combination Therapy-induced Febrile Neutropenia. ( Harasawa, H; Hashizume, J; Kodama, Y; Nakagawa, H; Nambu, M, 2023) |
| "The objective of the present study was to evaluate the effect of combination of telmisartan with 5-flourouracil (5-FU) in gastric cancer cachexia induced by administering N-methyl-N'-methyl-N-nitrosoguanidine (MNNG)." | 7.83 | Evaluation of role of telmisartan in combination with 5-fluorouracil in gastric cancer cachexia. ( Patel, BM; Patel, HJ; Sukumaran, S, 2016) |
| "To clarify the potential of parathyroid hormone-related protein (PTHrP) and interleukin-6 (IL-6) as cachectic factors in a colon 26 model and the effects of capecitabine on cancer cachexia as determined by plasma levels of IL-6 and PTHrP and body weight loss." | 7.74 | Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. ( Fujimoto-Ouchi, K; Mori, K; Onuma, E; Shirane, M; Tanaka, Y, 2007) |
| "Unfortunately, complexity in treating cachexia is amplified by both the underlying malignancy and the anti-cancer therapy which can independently promote cachexia." | 5.72 | Quercetin Improved Muscle Mass and Mitochondrial Content in a Murine Model of Cancer and Chemotherapy-Induced Cachexia. ( Bullard, BM; Cardaci, TD; Cunningham, P; Fan, D; McDonald, SJ; Murphy, EA; VanderVeen, BN; Velázquez, KT, 2022) |
| "Nedaplatin (NDP)/5-fluorouracil (5-FU) combination therapy frequently causes severe neutropenia and febrile neutropenia (FN)." | 4.31 | Poor Renal Function and a High Modified Glasgow Prognostic Score Are Predictive Factors for Nedaplatin/5-Fluorouracil Combination Therapy-induced Febrile Neutropenia. ( Harasawa, H; Hashizume, J; Kodama, Y; Nakagawa, H; Nambu, M, 2023) |
| "The objective of the present study was to evaluate the effect of combination of telmisartan with 5-flourouracil (5-FU) in gastric cancer cachexia induced by administering N-methyl-N'-methyl-N-nitrosoguanidine (MNNG)." | 3.83 | Evaluation of role of telmisartan in combination with 5-fluorouracil in gastric cancer cachexia. ( Patel, BM; Patel, HJ; Sukumaran, S, 2016) |
| "To clarify the potential of parathyroid hormone-related protein (PTHrP) and interleukin-6 (IL-6) as cachectic factors in a colon 26 model and the effects of capecitabine on cancer cachexia as determined by plasma levels of IL-6 and PTHrP and body weight loss." | 3.74 | Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. ( Fujimoto-Ouchi, K; Mori, K; Onuma, E; Shirane, M; Tanaka, Y, 2007) |
| "Pentoxifylline (PTX) is a drug that has been shown to have multiple beneficial effects in cancer patients through its anti-inflammatory properties." | 3.01 | Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). ( Baider, L; Barak, V; Meirovitz, A; Peretz, T; Stephanos, S, 2021) |
| "Patients with pancreatic cancer commonly suffer from exocrine pancreatic insufficiency, and the ingestion of digestive enzyme supplements may improve absorption." | 2.87 | Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. ( Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K, 2018) |
| "Pancreatic cancer is an extremely aggressive malignancy." | 2.74 | An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinica ( Büchler, MW; Decker-Baumann, C; Harig, S; Jäger, D; Karapanagiotou-Schenkel, I; Märten, A; Ose, J; Rötzer, I; Schmidt, J; Wente, MN, 2009) |
| "Unfortunately, complexity in treating cachexia is amplified by both the underlying malignancy and the anti-cancer therapy which can independently promote cachexia." | 1.72 | Quercetin Improved Muscle Mass and Mitochondrial Content in a Murine Model of Cancer and Chemotherapy-Induced Cachexia. ( Bullard, BM; Cardaci, TD; Cunningham, P; Fan, D; McDonald, SJ; Murphy, EA; VanderVeen, BN; Velázquez, KT, 2022) |
| "Cancer cachexia is a metabolic disorder involving perturbed energy balance and altered mitochondrial function." | 1.51 | Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. ( Barreto, R; Bonetto, A; Couch, ME; O'Connell, TM; Pin, F, 2019) |
| "Cachexia affects the majority of cancer patients, with currently no effective treatments." | 1.43 | Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. ( Barreto, R; Bonetto, A; Gao, H; Liu, Y; Waning, DL; Zimmers, TA, 2016) |
| " Here, we investigated whether the IMD in combination with chemotherapy could prevent cancer cachexia in colon 26 tumor-bearing mice." | 1.42 | An Immune-Modulating Diet in Combination with Chemotherapy Prevents Cancer Cachexia by Attenuating Systemic Inflammation in Colon 26 Tumor-Bearing Mice. ( Nakamura, K; Sasayama, A; Takahashi, T; Yamaji, T, 2015) |
| "Cancer cachexia is characterised by the loss of body mass and directly compromises immune response and the quality of life of cancer patients." | 1.38 | Improving cachectic symptoms and immune strength of tumour-bearing mice in chemotherapy by a combination of Scutellaria baicalensis and Qing-Shu-Yi-Qi-Tang. ( Chan, YL; Li, TL; Wang, H; Wu, CJ, 2012) |
| " Consequently, they are either excluded from antitumor therapy or receive only reduced dosage regimens." | 1.26 | [Parenteral feeding during aggressive chemotherapy of various neoplasms]. ( Jehn, U; Kohlschütter, B, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 5 (20.83) | 2.80 |
| Authors | Studies |
|---|---|
| Meirovitz, A | 1 |
| Baider, L | 1 |
| Peretz, T | 1 |
| Stephanos, S | 1 |
| Barak, V | 1 |
| VanderVeen, BN | 2 |
| Cardaci, TD | 2 |
| McDonald, SJ | 2 |
| Madero, SS | 1 |
| Unger, CA | 1 |
| Bullard, BM | 2 |
| Enos, RT | 1 |
| Velázquez, KT | 2 |
| Kubinak, JL | 1 |
| Fan, D | 2 |
| Murphy, EA | 2 |
| Cunningham, P | 1 |
| Hashizume, J | 1 |
| Nambu, M | 1 |
| Nakagawa, H | 1 |
| Harasawa, H | 1 |
| Kodama, Y | 1 |
| Mora, S | 1 |
| Adegoke, OAJ | 1 |
| Barreto, R | 3 |
| Kitase, Y | 1 |
| Matsumoto, T | 1 |
| Pin, F | 2 |
| Colston, KC | 1 |
| Couch, KE | 1 |
| O'Connell, TM | 2 |
| Couch, ME | 3 |
| Bonewald, LF | 1 |
| Bonetto, A | 3 |
| Abe, K | 1 |
| Uwagawa, T | 1 |
| Haruki, K | 1 |
| Takano, Y | 1 |
| Onda, S | 1 |
| Sakamoto, T | 1 |
| Gocho, T | 1 |
| Yanaga, K | 1 |
| Kays, JK | 1 |
| Shahda, S | 1 |
| Stanley, M | 1 |
| Bell, TM | 1 |
| O'Neill, BH | 1 |
| Kohli, MD | 1 |
| Koniaris, LG | 1 |
| Zimmers, TA | 2 |
| Nakamura, K | 1 |
| Sasayama, A | 1 |
| Takahashi, T | 1 |
| Yamaji, T | 1 |
| Khemissa, F | 1 |
| Mineur, L | 1 |
| Amsellem, C | 1 |
| Assenat, E | 1 |
| Ramdani, M | 1 |
| Bachmann, P | 1 |
| Janiszewski, C | 1 |
| Cristiani, I | 1 |
| Collin, F | 1 |
| Courraud, J | 1 |
| de Forges, H | 1 |
| Dechelotte, P | 1 |
| Senesse, P | 1 |
| Sukumaran, S | 1 |
| Patel, HJ | 1 |
| Patel, BM | 1 |
| Waning, DL | 1 |
| Gao, H | 1 |
| Liu, Y | 1 |
| Perboni, S | 1 |
| Bowers, C | 1 |
| Kojima, S | 1 |
| Asakawa, A | 1 |
| Inui, A | 1 |
| Xavier, MH | 1 |
| Vergueiro, Tde R | 1 |
| Vilar, EG | 1 |
| Pinto, JM | 1 |
| Issa, MC | 1 |
| Pereira, GB | 1 |
| Carocha, AP | 1 |
| Märten, A | 1 |
| Wente, MN | 1 |
| Ose, J | 1 |
| Büchler, MW | 1 |
| Rötzer, I | 1 |
| Decker-Baumann, C | 1 |
| Karapanagiotou-Schenkel, I | 1 |
| Harig, S | 1 |
| Schmidt, J | 1 |
| Jäger, D | 1 |
| Ferrucci, LM | 1 |
| Bell, D | 1 |
| Thornton, J | 1 |
| Black, G | 1 |
| McCorkle, R | 1 |
| Heimburger, DC | 1 |
| Saif, MW | 1 |
| Wang, H | 1 |
| Chan, YL | 1 |
| Li, TL | 1 |
| Wu, CJ | 1 |
| Fujimoto-Ouchi, K | 1 |
| Onuma, E | 1 |
| Shirane, M | 1 |
| Mori, K | 1 |
| Tanaka, Y | 1 |
| Lawson, DH | 1 |
| Nixon, DW | 1 |
| Kutner, MH | 1 |
| Heymsfield, SB | 1 |
| Rudman, D | 1 |
| Moffitt, S | 1 |
| Ansley, J | 1 |
| Chawla, R | 1 |
| Le Bricon, T | 1 |
| Gugins, S | 1 |
| Cynober, L | 1 |
| Baracos, VE | 1 |
| Kohlschütter, B | 1 |
| Jehn, U | 1 |
| Copeland, EM | 1 |
| MacFadyen, BV | 1 |
| Lanzotti, VJ | 1 |
| Dudrick, SJ | 1 |
| Loprinzi, CL | 1 |
| Miser, AW | 1 |
| Kardinal, C | 1 |
| Everson, LK | 1 |
| Ahlquist, DA | 1 |
| Dose, AM | 1 |
| Moertel, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer[NCT06115174] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Open-label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution Versus Best Supportive Nutritional Care in Patients With Pancreatic Cancer Receiving 2nd Line Chemotherapy[NCT01362582] | Phase 3 | 32 participants (Actual) | Interventional | 2010-03-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for fluorouracil and Cachexia
| Article | Year |
|---|---|
Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I).
Topics: Aged; Antineoplastic Agents; Cachexia; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; | 2021 |
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplas | 2018 |
A phase III study evaluating oral glutamine and transforming growth factor-beta 2 on chemotherapy-induced toxicity in patients with digestive neoplasm.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Dietary Supplements; Double-Blind Me | 2016 |
An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinica
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Fluorouracil; | 2009 |
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study.
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Body Weight; Cachexia; Capecitabine; Combined Modal | 2011 |
Cancer control research in the North Central Cancer Treatment Group (NCCTG).
Topics: Allopurinol; Anorexia; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Colorectal Neoplas | 1989 |
18 other studies available for fluorouracil and Cachexia
| Article | Year |
|---|---|
Obesity reduced survival with 5-fluorouracil and did not protect against chemotherapy-induced cachexia or immune cell cytotoxicity in mice.
Topics: Animals; Antineoplastic Agents; Cachexia; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Mice; Ne | 2022 |
Quercetin Improved Muscle Mass and Mitochondrial Content in a Murine Model of Cancer and Chemotherapy-Induced Cachexia.
Topics: Animals; Antineoplastic Agents; Cachexia; Disease Models, Animal; Fluorouracil; Mice; Mitochondria; | 2022 |
Poor Renal Function and a High Modified Glasgow Prognostic Score Are Predictive Factors for Nedaplatin/5-Fluorouracil Combination Therapy-induced Febrile Neutropenia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Febrile Neutropenia; Fluorouracil | 2023 |
The effect of a chemotherapy drug cocktail on myotube morphology, myofibrillar protein abundance, and substrate availability.
Topics: Animals; Blotting, Western; Cachexia; Cells, Cultured; Cisplatin; Drug Therapy, Combination; Fluorou | 2021 |
ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2017 |
Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer.
Topics: Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Weights | 2018 |
Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Camptothec | 2019 |
An Immune-Modulating Diet in Combination with Chemotherapy Prevents Cancer Cachexia by Attenuating Systemic Inflammation in Colon 26 Tumor-Bearing Mice.
Topics: Animals; Antineoplastic Agents; Blood Glucose; Cachexia; Cell Line, Tumor; Colon; Colonic Neoplasms; | 2015 |
Evaluation of role of telmisartan in combination with 5-fluorouracil in gastric cancer cachexia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Benzoates; Cachexia; Fluoro | 2016 |
Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Compositio | 2016 |
Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice.
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Appetite Stimulants; Body Weight; Cachexia; Cell | 2008 |
Cutaneous metastasis of gastric adenocarcinoma: an exuberant and unusual clinical presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cachexia; Carcinoma, Signet Ring Cell; Etoposide; Fl | 2008 |
Improving cachectic symptoms and immune strength of tumour-bearing mice in chemotherapy by a combination of Scutellaria baicalensis and Qing-Shu-Yi-Qi-Tang.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cachexia; Carcinoma, Lewis Lu | 2012 |
Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.
Topics: Animals; Cachexia; Capecitabine; Cell Line; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hypercal | 2007 |
Enteral versus parenteral nutritional support in cancer patients.
Topics: Animals; Cachexia; Enteral Nutrition; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; | 1981 |
Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats.
Topics: Animals; Antineoplastic Agents; Cachexia; Cisplatin; Cyclophosphamide; DNA; Eating; Female; Fluorour | 1995 |
[Parenteral feeding during aggressive chemotherapy of various neoplasms].
Topics: Adult; Bleomycin; Body Weight; Cachexia; Cyclophosphamide; Fluorouracil; Humans; Methotrexate; Middl | 1978 |
Intravenous hyperalimentation as an adjunct to cancer chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Body Weight; Cachexia; Evaluation Studies as Topic; Fe | 1975 |